TET2 and myeloid neoplasm: Around 60% of CD34+ cells from patient 2 [P2(h)] exhibited a heterozygous JAK2V617F mutation (JAK2V617F/WT) whereas no mutation was identified in these cells in ASXL1 and the other genes involved in myeloid malignancies, including TET2, EZH2, DNMT3A, IDH1 and SRSF2 [6].